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Introduction
Fluoroquinolones, inhibitors of bacterial DNA gyrase, exhibit strong antibacterial activities against variety bacteria, especially aerobic Gram-negative organisms.
Orally administrated fluoroquinolones are widely distributed throughout the body following rapid absorption from the intestine. Many fluoroquinolones undergo either hepatic or renal elimination. Metabolism accounts for the hepatic elimination of fluoroquinolones, and biliary excretion is usually a minor elimination pathway. However, it has been reported that the concentrations of ciprofloxacin in the bile are far greater than the usual minimal inhibitory concentration of common biliary pathogens in humans, presumably due to active transport since the ratio of the concentrations of ciprofloxacin in bile/liver was greater than unity (Dan et al., 1987) . Prulifloxacin, an ester type prodrug of ulifloxacin, is immediately metabolized to ulifloxacin in the intestine, and ten percent is recovered in the bile (Nakashima et al., 1994) . Grepafloxacin and sparfloxacin are mainly eliminated from the liver by metabolism and biliary excretion, but very little is excreted into urine (Efthymiopoulos et al., 1997; Kamberi et al., 1998) .
Although their ability to undergo biliary excretion is one of the crucial factors for their therapeutic efficacy against bile duct infections, the underlying mechanism of fluoroquinolones has not been fully investigated. A number of reports have shown that several kinds of transporters are expressed on the canalicular membrane in the liver and are responsible for the efficient elimination of drugs into the bile (Chandra and Brouwer, 2004; Pauli-Magnus and Meier, 2006; Shitara et al., 2006) . It is DMD #14969 generally accepted that the transport of a variety of anionic drugs across the canalicular membrane is mainly mediated by multidrug resistance-associated protein 2 (MRP2/ABCC2), and some hydrophobic cationic drugs are eliminated into the bile by P-glycoprotein (Schinkel et al., 1995; Chandra and Brouwer, 2004) .
The biliary excretion of grepafloxacin is partly mediated by MRP2 since the biliary excretion of grepafloxacin was significantly reduced in MRP2 deficient mutant rats (EHBR) (29% of normal rats) (Sasabe et al., 1998) . Although grepafloxacin is a substrate of P-gp, its biliary excretion is unchanged in Mdr1a/1b (-/-) mice, excluding the involvement of P-gp (Sasabe et al., 2004) . For ulifloxacin, neither MRP2 nor P-gp is involved in its biliary excretion (Yagi et al., 2003) . Therefore, other transporters have been hypothesized to account for the biliary excretion of UFX and GPFX.
Breast cancer resistance protein (BCRP/ABCG2) is the half-size ABC transporter identified on the bile canalicular membrane (Maliepaard et al., 2001; Jonker et al., 2002) . In vivo studies using Bcrp (-/-) mice have shown that BCRP accounts for the biliary excretion of PhIP, pitavastatin and methotrexate Mao and Unadkat, 2005 Pulido et al., 2006) . Therefore, it is possible that BCRP plays a significant role in the biliary excretion of fluoroquinolones. In the present study, in vivo studies using Bcrp (-/-) mice were DMD #14969 6 carried out to determine the contribution of BCRP to the biliary excretion of fluoroquinolones. In addition to the liver, BCRP is expressed in the luminal membrane of the brain capillaries and renal proximal tubules (Jonker et al., 2002; Lee et al., 2005) . The brain is a target organ for the adverse effects (epileptogenic neurotoxicity), of fluoroquinolones and the kidney is another elimination organ.
The tissue-to-plasma partition coefficients were determined in these tissues to determine the involvement of BCRP in the efflux transport of fluoroquinolones.
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Material and Methods
Animals
Male Bcrp (-/-) and wild-type FVB mice (16-18 weeks old) were used in the present study. Bcrp (-/-) mice were established previously (Jonker et al., 2002) .
All animals were maintained under standard conditions with a reverse dark light cycle and were treated humanely. Food and water were available ad libitum. The studies reported in this manuscript were carried out in accordance with the guidelines provided by the Institutional Animal Care Committee (Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan).
Materials
UFX was a gift from Meiji Seika (Tokyo, Japan). GPFX and OFX were gifted from Otsuka Pharmaceutical Company (Tokyo, Japan). CPFX and sulfobromophthalein were purchased from ICN Biomedicals, Inc (Aurora, OH) and
Sigma-Aldrich (St.Louis, MO), respectively. Ko143 was supplied from Dr.Schinkel (Allen et al., 2002) . Parent MDCK ll cells were kindly provided by Dr.Piet Borst.
All other chemicals were of analytical grade and were commercially available.
Cell Culture
MDCK II cells were grown in Dulbecco's modified Eagle's medium low glucose (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (Sigma-Aldrich), 100 U/ml penicillin, and 100 µg/ml streptomycin at 37°C with 5% CO 2 and at 95% humidity.
Transcellular Transport Study
This article has not been copyedited and formatted. The final version may differ from this version. MDCK II cells were seeded in 24-well plates at a density of 1.4 x 10 5 cells/well . 
In Vivo Study in Mice
Male FVB and Bcrp (-/-) mice weighing approximately 25 to 36 g were used throughout these experiments. Under urethane anesthesia (1.5 mg/kg), the gallbladder was ligated and the bile duct was cannulated with a Teflon catheter (UT-03, Unique medical co., Ltd, Tokyo, Japan) for bile collection. The mice received a bolus administration of each fluoroquinolone at a dose of 1 mg/kg via the jugular vein. Blood samples were collected from the opposite jugular vein at 7.5, 15, 30, 60 and 120 min. Bile was collected in preweighed test tubes at 30-min intervals throughout the experiments. Plasma was prepared by centrifugation of the blood samples. The mice were sacrificed after 120 min, and the entire liver, kidney and brain were excised immediately. The tissues were weighed and stored at -80°C until quantification. Portions of liver, kidney and brain were added to two volumes of PBS (w/v) and homogenized. Plasma (25 µl), bile (10 µl), or tissue homogenate (100 µl) was deproteinized with two volumes of methanol containing 0.15% formic acid (w/v), followed by centrifugation at 4°C and 10,000g for 10 min.
The supernatant was diluted with 0.05% formic acid solution and analyzed using the LC/MS system (Shimadzu Scientific Instruments). No chromatographic interference was found with regard to these fluoroquinolones in extracts from blank plasma, bile, and tissue homogenates. We measured the calibration curve before and after each sample analysis, and did not observe any significant inter-and intraday difference. The calibration range was from 0.01 to 3µM. The dilution factor range of supernatants of plasma, bile and tissues in this study was 1-10, 15-30 and 2-3, respectively. Each calibration curve was constructed using proper matrices, such as plasma supernatant and diluted plasma supernatant. BSP dissolved in 0.9% saline was infused into a jugular vein through a catheter at a rate of 90.5 mg/hr/kg (5 ml/hr/kg) throughout the experiments (Horikawa et al., 2002) . Twenty minutes after starting the infusion, GPFX was administered at a dose of 1 mg/kg via the jugular vein. The sample preparation and quantification of GPFX was performed as described above.
Inhibition study by BSP of biliary excretion of GPFX
Pharmacokinetic Analysis
The total plasma clearance (CL total ), biliary excretion clearance normalized by circulating plasma (CL bile, plasma ), and apparent intrinsic biliary excretion clearance (CL bile, liver, app ) were calculated using following equations: AUC was calculated using trapezoidal method. Plasma concentration at 0 min and the time when plasma concentration was diminished were acquired by the extrapolation.
Determination of fluoroquinolones in the specimens
The LC We compared the translocation of GPFX in the basal-to-apical direction for 120 min was approximately 10-and 4.0-fold greater than that in the opposite direction in hBCRP-and mBcrp-MDCK, respectively, which was identical in GFP-MDCK ( Figure. 1) . The translocation of UFX in the basal-to-apical direction for 120 min was slightly increased; 1.8-and 1.5-fold of that in the opposite direction in hBCRPand mBcrp-MDCK cells, respectively ( Figure. 2), whereas that in the control was 0.6-fold. The ratio of the transcellular transport at 180 min (basal-to-apical / apical-to-basal) was greater than that in the presence of Ko143: 9.1-and 3.8-fold for GPFX, and 3.0-and 2.4-fold for UFX respectively, 9.87 versus 1.17, 4.05 versus 1.09, 1.84 versus 0.84 and 1.46 versus 0.47 ( Table. 1 Table 2 . There was no significant difference in the plasma clearance of all fluoroquinolones in Bcrp (-/-) and FVB mice. The CL bile, p of CPFX, GPFX and UFX was significantly reduced, but the reduction in the CL bile, p of OFX was not statistically significant.
The tissue-to-plasma concentration ratios in BCRP expressing tissues such as liver, brain and kidney were determined.
In the liver and brain, the tissue-to-plasma concentration ratios of all fluoroquinolones were unchanged, whereas those of CPFX and GPFX in kidney were increased in Bcrp (-/-) mice (Table 2) .
Inhibition study of MRP2 mediated biliary excretion of GPFX in Bcrp (-/-) mice using BSP infusion.
BSP administration caused no significant differences in the plasma total body clearance in Bcrp (-/-) mice with and without BSP infusion, but the cumulative biliary excretion of GPFX was reduced by BSP ( Figure. 4) . The CL bile, p of GPFX was slightly changed but this was not statistically significant. The liver-to-plasma concentration ratio of GPFX was higher in the BSP-treated group, while the CL bile, liver, app was significantly reduced in the BSP-treated group (Table 3) .
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Discussion
In this study, we investigated the involvement of BCRP in the biliary excretion and tissue distribution of fluoroquinolones using Bcrp (-/-) mice.
To show that they are substrates of BCRP, their transcellular transport across monolayers of MDCK ll cells was determined. BCRP is expressed on the apical membrane of MDCK ll cells , and Merino et al reported that the basal-to-apical transport of CPFX and OFX was increased in hBCRP-and mBcrp-MDCK, which was reduced in the presence of Ko143, a BCRP specific inhibitor . Consistent with other fluoroquinolones, exogenous expression of hBCRP/mBcrp induced directional transport of GPFX in the basal-to-apical direction, which was reduced by a BCRP inhibitor, Ko143 (Figure 1 ).
Expression of hBCRP/mBcrp also significantly increased the Ko143-sensitive basal-to-apical transport of UFX ( Figure 2) . The ratios of the transcellular transport of UFX in hBCRP/mBcrp expressing cells were smaller than those of GPFX (Table 1) , indicating that GPFX is a better hBCRP/mBcrp substrate with greater transport activities. Unlike GPFX, the apical-to-basal transport of UFX was greater than its basal-to-apical transport in control MDCK cells, suggesting that endogenous transporter(s) facilitate the apical-to-basal transport ( Table 1) the liver in rats in a study that compared the hepatic clearance of GPFX with the hepatic uptake clearance (Sasabe et al., 1997) .
Although GPFX is a mBcrp substrate with greater transport activity than UFX, the magnitude of the reduction in the biliary excretion clearance of GFPX was lower than that of UFX. Since involvement of MRP2 in the biliary excretion of GPFX has been suggested by in vivo kinetic analysis using EHBR, the discrepancy may be explained by the smaller contribution of mBcrp to the net canalicular efflux process of GPFX. This possibility was investigated by examining an inhibitory effect of BSP on the biliary excretion of GPFX. BSP caused only a minimal difference in the CL bile, p in Bcrp (-/-) mice. However, taking the greater hepatic concentration in the BSP-treated group into the consideration, the biliary excretion clearance with regard to the hepatic concentration will be significantly inhibited, suggesting an involvement of BSP-sensitive efflux transporter at the canalicular membrane, presumably MRP2. The increased hepatic concentration produced by BSP may be ascribed to an inhibition of hepatic metabolism and/or sinusoidal efflux of GPFX. Considering the kinetic analyses by Sasabe et al (1997) , it can be speculated that BSP inhibits the sinusoidal efflux of GPFX. This hypothesis should be investigated using the in situ perfusion technique to compare the concentration time profile in the outflow in mice treated with and without BSP.
In addition to the liver, we observed that the kidney-to-plasma concentration ratio of CPFX and GPFX is 3.6 and 1.5 times higher in Bcrp (-/-) mice than that in FVB mice. Although very little GPFX is excreted into the urine in rats (Sasabe et al., 1998) , the urinary excretion accounts for the 50% of the total body clearance in EHBRs (Nouaille-Degorce et al., 1998) . BCRP may play a significant role in the urinary excretion of CPFX as well as its biliary excretion. It should be noted that the protein expression of BCRP was below the limit of detection in human kidney (Maliepaard et al., 2001) . Since CPFX undergoes tubular secretion in humans, which is inhibited by probenecid (Jaehde et al., 1995) , other transporters will account for the luminal efflux of CPFX in humans.
Epileptogenic neurotoxicity is a well-known central nervous system side effect of fluoroquinolones and, thus, the transport of BBB is a critical factor for this adverse effect together with the inhibition potency of GABA receptors. Fluoroquinolones have been suggested to undergo active efflux at the BBB because the steady-state brain interstitial space concentration of fluoroquinolones was markedly lower than their plasma unbound concentrations (Ooie et al., 1997b) , and the permeability surface area product of the efflux transport was 10-300 fold greater than the uptake clearance (Ooie et al., 1997a) . Using P-gp knockout mice, P-gp has been shown This article has not been copyedited and formatted. The final version may differ from this version. to limit the brain uptake of GPFX and UFX (Murata et al., 1999; Sasabe et al., 2004) .
The present study has demonstrated the limited role of Bcrp in the efflux transport of fluoroquinolones at the BBB, and, unlike the liver, P-gp is likely responsible for major efflux transport of fluoroquinolones at the BBB. The mRNA quantification of Mdr1a showed more abundant expression in the cerebral cortex than in the liver (Brady et al., 2002) , and vice versa for Bcrp (Tanaka et al., 2005) . This may explain the tissue-selective contribution of P-gp and Bcrp to the net efflux process in the liver and brain.
This study showed that Bcrp is involved in the biliary excretion of CPFX, GPFX, OFX and UFX. The hepatic expression of BCRP is influenced by gender, the greater expression in males than females (Merino et al., 2005) . Consistent with hepatic expression, the biliary excretion of nitrofurantoin and PhIP was greater in male mice (Merino et al., 2005) . Therefore, gender could be a critical factor affecting the therapeutic efficacy of fluoroquinolones for the treatment of bile duct infections. In addition to gender, there are genetic factors affecting the therapeutic efficacy. A genetic polymorphism (C421A) substituting Gln for Lys is associated with the low protein expression of BCRP, and this SNP is frequently found particularly in the Japanese population (20-30%) (Kondo et al., 2004) . Further studies are necessary to investigate interindividual difference of BCRP activity in the liver.
In conclusion, Bcrp plays a significant role in the biliary excretion of fluoroquinolones, and in the urinary excretion of CPFX and GPFX, but only a limited 
